Back to results
US 2006/0079569 A1Published application
Antidepressant oral liquid compositions
AssigneeWockhardt Limited
InventorRamesh Sesha
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeWockhardt Limited
InventorRamesh Sesha
Estimating the term…
The invention provides for the first time an oral liquid composition of duloxetine or its pharmaceutically equivalent derivatives like salts, isomers, complexes, polymorphs, hydrates or esters thereof. The duloxetine or its pharmaceutically equivalent derivative is present from about 2 mg to approximately 200 mg; and a buffering agent was used to stabilize the acid sensitive duloxetine. The composition has duloxetine from about 0.1 meq to about 2.5 mEq per mg of duloxetine. The invention further discloses an oral liquid composition of duloxetine or its pharmaceutically equivalent derivative wherein the degradation product 1-Naphthol is less than 0.01%. Also provided is a method for treating of major depressive disorder and or diabetic peripheral neuropathic pain comprising administering to a mammal in need of such treatment a therapeutically effective amount of a composition.
An oral liquid composition of duloxetine or its pharmaceutically equivalent salts, isomers, complexes, polymorphs, hydrates or esters
A oral liquid composition of duloxetine or its pharmaceutically equivalent salts, isomers, complexes, polymorphs, hydrates or esters thereof wherein the rate of absorption is at least 10 minutes lower than a conventional solid pharmaceutical composition
A oral liquid composition of duloxetine or its pharmaceutically equivalent salts, isomers, complexes, polymorphs, hydrates or esters thereof wherein the maximal plasma concentrations (Cmax) of duloxetine occurring between from about 10 to about 90 minutes from the time of administration
A method for the treatment of major depressive disorder comprising administering to a host in need of such treatment a therapeutically effective amount of an oral liquid composition comprising duloxetine or its pharmaceutically equivalent derivative
A method for the treatment of diabetic peripheral neuropathic pain comprising administering to a host in need of such treatment a therapeutically effective amount of an oral liquid composition comprising duloxetine or its pharmaceutically equivalent derivative.
An oral liquid composition comprising duloxetine or its pharmaceutically equivalent derivative wherein 1-Naphthol is present in less than 0.2%
Dependencies are inferred from the claim text.